Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2005-09-13
2005-09-13
Canella, Karen A. (Department: 1642)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C424S277100
Reexamination Certificate
active
06942862
ABSTRACT:
Methods and compositions to elicit or enhance immunity in humans against self tumor antigens are disclosed. Such immunity is generated by immunization with homologous foreign proteins. Self tumor antigens include protein expression products of overexpressed human oncogenes, such as human HER-2
eu protein, and organ-specific or tissue-specific differentiation antigens, such as PAP or PSA, associated with tumor cells.
REFERENCES:
patent: 4205130 (1980-05-01), Vihko
patent: 4267272 (1981-05-01), Josephson
patent: 4510239 (1985-04-01), Miller et al.
patent: 5679647 (1997-10-01), Carson et al.
patent: 5719030 (1998-02-01), Kuroiwa et al.
patent: 5738867 (1998-04-01), Spitler
patent: 5925362 (1999-07-01), Spitler et al.
patent: 5976546 (1999-11-01), Laus et al.
patent: 6080409 (2000-06-01), Laus et al.
patent: 1 185 525 (1985-04-01), None
patent: WO 95/04548 (1995-02-01), None
patent: WO 98/46769 (1998-10-01), None
Chatta et al, Induction of immunity to rat prostatic phosphatase (PAP): Implications for prostate cancer immunotherapy. Proc. Annu Meet Am Assoc Cancer Res, Mar. 1997, vol. 38, p. A2703.
Dryberg and Oldstone, Peptides as Probes ro Study Molecular Mimicry and Virus-Induced Autoimmunity, in: CCurrent Topics in Microbiology and Immunology, 1986, vol. 130, pp. 25-37.
Mamula et al, “Mechanisms of autoimmunity: Cryptic self polypeptides break T-cell tolerance to self-intracellular proteins”, Arthritis and Rheumatism, 1992, vol. 35, No. 9, suppl., p. S38.
Fedoseyeva et al, “Induction of T cell responses to a self-antigen following allotransplantation”, Transplantation, Mar. 15, 1996, vol. 61, pp. 679-683.
Mahi-Brown et al, “The cellular response to immunization with zona pellucida antigens”, Journal of Reproductive Immunology, 1992, vol. 21, pp. 29-46.
Bowie et al (Science, 257:1306-1310), 1990.
Herbert et al (Dictionary of Immunology, Academic Press, London, p. 58), 1990.
Bakker et al., “Melanocyte Lineage-specific Antigen gp100 Is Recognized by Melanoma-derived Tumor-infiltrating Lymphocytes,”The Journal of Experimental Medicine 179:1005-1009, 1994.
Baselga et al., “Phase II Study of Weekly Intravenous Recombinant Humanized Anti-p185-HER2Monoclonal Antibody in Patients With HER2
eu-Overexpressing Metastatic Breast Cancer,”Journal of Clinical Oncology 14(3):737-744, 1996.
Ben-Mahrez et al., “Circulating Antibodies Against C-MYC Oncogene Products In Sera Of Colorectal Cancer Patients,”Int. J. Cancer 46:35-38, 1990.
Berchuck et al., “Overexpression of HER-2
eu Is Associated with Poor Survival in Advanced Epithelial Ovarian Cancer,”Cancer Research 50:4087-4091, 1990.
Bernards et al., “Effective tumor immunotherapy directed against an oncogene-encoded product using a vaccinia virus vector, ”Proc. Natl. Acad. Sci. USA 84:6854-6858, 1987.
Cheever et al., “Specific Adoptive Therapy Of Established Leukemia With Syngeneic Lymphocytes Sequentially Immunized In Vivo And In Vitro And Nonspecifically Expanded By Culture With Interleukin 2,”The Journal Of Immunology 126(4): 1318-1322, 1981.
Disis and Cheever, “HER-2
eu Protein: A Target for Antigen-Specific Immunotherapy of Human Cancer,”Advances in Cancer Research 71:343-371, 1997.
Disis et al., “Existent T-Cell and Antibody Immunity to HER-2
eu Protein in Patients with Breast Cancer,”Cancer Research 54:16-20, 1994.
Disis et al., “Immunity to the HER-2
eu oncogenic protein,”. inVaccines Against Virally Induced Cancers, John Wiley & Sons, Chichester, 1994, CIBA Foundation Symposium 187, pp. 198-211.
Disis et al., “Peptide-Based, but Not Whole Protein, Vaccines Elicit Immunity to HER-2
eu, an Oncogenic Self Protein,”The Journal of Immunology 156:3151-3158, 1996.
Disis et al., “Immunization with Homologous Foreign Proteins Generates Immunity Against “Self” Tumor Antigens,”The FASEB Journal Abstracts 10(6):p. A1470, Abstract No. 2709, 1996.
Fisk et al., “Identification of an Immunodominant Peptide of HER-2
eu Protooncogene Recognized by Ovarian Tumor-specific Cytotoxic T Lymphocyte Lines,”J. Exp. Med. 181:2109-2117, 1995.
Gaugler et al., “Human Gene MAGE-3 Codes for an Antigen Recognized on a Melanoma by Autologous Bytolytic T Lymphocytes,”J. Exp. Med. 179:921-930, 1994.
Gusterson et al., “Prognostic Importance of c-erbB-2 Expression in Breast Cancer,”Journal of Clinical Oncology 10(7): 1049-1056, 1992.
Houghton, “Cancer Antigens: Immune Recognition of Self and Altered Self,”J. Exp. Med. 180:1-4, 1994.
Katsumata et al., “Prevention of breast tumor development in vivo by downregulation of the p185neureceptor,”Nature Medicine I(7):644-648, 1995.
Kawakami et al., “Identification of the Immunodominant Peptides of the MART-1 Human Melanoma Antigen Recognized by the Majority of HLA-A2-restricted Tumor Infiltrating : Lymphocytes,”The Journal of Experimental Medicine 180:347-352, 1994.
Kern et al., “p185neuExpression in Human Lung Adenocarcinomas Predicts Shortened Survival,”Cancer Research 50:5184-5191, 1990.
Mahi-Brown et al., “The cellular immune response to immunization with zona pellucida antigens,”Journal of Reproductive Immunology 21:29-46, 1992.
Mamula et al., “Breaking T Cell Tolerance With Foreign And Self CO-Immunogens. A Study of Autoimmune B and T Cell Epitopes of Cytochrome c,”The Journal of Immunology 149(3):789-195, 1992.
Mamula, “The Inability to Process a Self-Peptide Allows Autoreactive T Cells to Escape Tolerance,”J. Exp. Med. 177:567-571, 1993.
Matyas et al., “Onco Vax_PTM vaccine for prostate cancer induces immune responses to prostate specific antigen in prostate cancer patients,”Proceedings of the American Association for Cancer Research Annual Meeting 40:576-577, 1999.
Naftzger et al., “Immune response to a differentiation antigen induced by altered antigen: A study of tumor rejection and autoimmunity,”Proc. Natl. Acad. Sci. USA 93:14809-14814, 1996.
Nanda and Sercarz, “Induction of Anti-Self-Immunity to Cure Cancer,”Cell 82:13-17, 1995.
Peoples et al., “Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2
eu-derived peptide,”Proc. Natl. Acad. Sci. USA 92:432-436, 1995.
Schlichtholz et al., “The Immune Response to p53 in Breast Cancer Patients Is Directed against Immunodominant Epitopes Unrelated to the Mutational Hot Spot,”Cancer Research 52:6380-6384, 1992.
Skinner et al., “Characterization of antigenicity and immunogenicity pattern of native and recombinant zona pellucida proteins in the white-tailed deer (Oidocoileus virginianus),”Journal of Reproduction and Fertility 101:295-303, 1994.
Slamon et al., “Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2
eu Oncogene,”Science 235:177-182, 1987.
Takahashi et al., “Antibody to ras Proteins in Patients with Colon Cancer,”Clinical Cancer Research 1:1071-1077, 1995.
Talmadge et al.; “Preclinical evaluation of OncoVax-P a prostate cancer vaccine,”Proceedings of the American Association for Cancer Research Annual Meeting 37:p. 477, 1996.
Yonemura et al., “Evaluation of Immunoreactivity for erB-2 Protein as a Marker of Poor Short Term Prognosis in Gastric Cancer,”Cancer Research 51:1034-1038, 1991.
Mamula et al., “B Cells Process and Present Lupus Autoantigens that Initiate Autoimmune T Cell Responses,”J. Immun. 152:1453-1461, 1994.
Cheever Martin A.
Disis Mary L.
Canella Karen A.
Seed IP Law Group
University of Washington
LandOfFree
Methods and compositions to generate immunity in humans... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions to generate immunity in humans..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions to generate immunity in humans... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3390346